연구성과로 돌아가기
2023 연구자 정보 (31 / 1135)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Park, Y. S. (Park, YS) |
|
|
[JCR상위 1.1] Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach | SCIE | 1.1 | ONCOLOGY | ||||
|
Park, Yeon Hee (Park, YH) |
Samsung Med Ctr, Seoul, South Korea Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea |
|
|
[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 [JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 [JCR상위 1.7] Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25) [JCR상위 33.1] Knowledge, attitudes, and behaviors toward fertility preservation in patients with breast cancer: A cross-sectional survey of physicians |
SCIE | 1.1 | ONCOLOGY | heejeong_kim@amc.seoul.kr; | ||
|
Qiao, Liang (Qiao, L) |
교신저자 |
Univ Elect Sci & Technol China, Sch Phys, Chengdu 610054, Peoples R China Univ Elect Sci & Technol China, Yangtze Delta Reg Inst Huzhou, Huzhou 313001, Peoples R China |
A-8165-2012 Qiao, Liang |
0000-0003-2400-2986 Qiao, Liang |
[JCR상위 1.1] Exploration of metal organic frameworks and covalent organic frameworks for energy-related applications | SCIE | 1.1 | CHEMISTRY, INORGANIC & NUCLEAR | Jiabao.yi@newcastle.edu.au;liang.qiao@uestc.edu.cn; | |
|
Qin, S. (Qin, S) |
Nanjing Univ Chinese Med, Nanjing Jingdu Hosp, Canc Ctr, Jinling Hosp, Nanjing, Peoples R China Nanjing Univ Chinese Med, Nanjing Jingdu Hosp, Canc Ctr Jinling Hosp, Nanjing, Peoples R China Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China |
|
|
[JCR상위 1.1] Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis [JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 [JCR상위 68.8] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation |
SCIE | 1.1 | ONCOLOGY | |||
|
Raziq, Fazal (Raziq, F) |
Univ Elect Sci & Technol China, Sch Phys, Chengdu 610054, Peoples R China |
AAX-9966-2020 Raziq, Fazal |
|
[JCR상위 1.1] Exploration of metal organic frameworks and covalent organic frameworks for energy-related applications | SCIE | 1.1 | CHEMISTRY, INORGANIC & NUCLEAR | Jiabao.yi@newcastle.edu.au;liang.qiao@uestc.edu.cn; | ||
|
Ren, Z. (Ren, Z) |
Fudan Univ, Dept Hepat Oncol, Zhongshan Hosp, Shanghai, Peoples R China |
|
|
[JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | SCIE | 1.1 | ONCOLOGY | |||
|
Riaz, F. (Riaz, F) |
Stanford Sch Med, Med Oncol, Stanford, CA USA |
|
|
[JCR상위 1.1] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) | SCIE | 1.1 | ONCOLOGY | |||
|
Seol, Hyun-Joo (Seol, HJ) |
Kyung Hee Univ, Sch Med, Seoul, Seoul Tukpyolsi, South Korea |
|
|
[JCR상위 1.1] Impacts of tocolytics on maternal and neonatal glucose levels in women with gestational diabetes mellitus | SCIE | 1.1 | OBSTETRICS & GYNECOLOGY | |||
|
Shah, Rahim (Shah, RH) |
제1저자 | Univ Elect Sci & Technol China, Sch Phys, Chengdu 610054, Peoples R China |
|
|
[JCR상위 1.1] Exploration of metal organic frameworks and covalent organic frameworks for energy-related applications | SCIE | 1.1 | CHEMISTRY, INORGANIC & NUCLEAR | Jiabao.yi@newcastle.edu.au;liang.qiao@uestc.edu.cn; | |
|
Shah, Sayed (Shah, SY) |
Soochow Univ, Soochow Inst Energy & Mat Innovat, Coll Phys Optoelect & Energy, Suzhou 215006, Peoples R China |
|
|
[JCR상위 1.1] Exploration of metal organic frameworks and covalent organic frameworks for energy-related applications | SCIE | 1.1 | CHEMISTRY, INORGANIC & NUCLEAR | Jiabao.yi@newcastle.edu.au;liang.qiao@uestc.edu.cn; | ||
|
Siegel, A. B. (Siegel, AB) |
Merck & Co Inc, Oncol Clin Res, Rahway, NJ USA |
|
|
[JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 | SCIE | 1.1 | ONCOLOGY | |||
|
Simon, H. (Simon, H) |
CHU Brest, Oncol, Hop Morvan, Inst Cancerol & Hematol, Brest, France |
|
|
[JCR상위 1.1] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) | SCIE | 1.1 | ONCOLOGY | |||
|
Sohn, Joo Hyuk (Sohn, JH) |
Yonsei Canc Ctr, Seoul, South Korea |
|
|
[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 | SCIE | 1.1 | ONCOLOGY | |||
|
Sugihara, Masahiro (Sugihara, M) |
Daiichi Sankyo Co Ltd, Tokyo, Japan Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan |
|
|
[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 | SCIE | 1.1 | ONCOLOGY | |||
|
Tamburini, E. (Tamburini, E) |
Pia Fdn Cardinale G Panico Hosp, Oncol & Palliat Care, Tricase, Italy |
LQJ-8211-2024 Tamburini, Emiliano |
|
[JCR상위 1.1] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) | SCIE | 1.1 | ONCOLOGY |
페이지 이동: